SEARCH

SEARCH BY CITATION

References

  • 1
    Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215219.
  • 2
    Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25(Suppl 1): 4047.
  • 3
    Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3(10 Suppl 2 ): S132S135.
  • 4
    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271285.
  • 5
    Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397405.
    Direct Link:
  • 6
    Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 10761084.
  • 7
    Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19: 9199.
  • 8
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 11751181.
  • 9
    El-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005; 12: 248253.
  • 10
    Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130: 497513.
  • 11
    Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35(5 Suppl 2 ): S86S91.
  • 12
    El-Aneed A, Banoub J. Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res 2006; 26: 32933300.
  • 13
    Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1 ): S108S112.
  • 14
    Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. HEPATOLOGY 2006; 44: 15181527.
  • 15
    Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513523.
    Direct Link:
  • 16
    Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83: 429439.
    Direct Link:
  • 17
    Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999; 1473: 2134.
  • 18
    Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 2006; 94: 287292.
  • 19
    Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429434.
  • 20
    Morelle W, Flahaut C, Michalski JC, Louvet A, Mathurin P, Klein A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006; 16: 281293.
  • 21
    Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. HEPATOLOGY 2005; 42: 14371445.
  • 22
    Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50: 12991300.
  • 23
    Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc 2006; 1: 397405.
  • 24
    Desmyter L, Fan YD, Praet M, Jaworski T, Vervecken W, De Hemptinne B, et al. Rating of CCl4-induced rat liver fibrosis by blood serum glycomics. J Gastroenterol Hepatol 2006;doi://10.1111/j.1440-1746.2006.04553.x. Available at: http://www.blackwell-synergy.com.
  • 25
    Giannini E, Risso D, Testa R. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients. Am J Gastroenterol 2001; 96: 918919.
    Direct Link:
  • 26
    Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19: 314318.
  • 27
    Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. Alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004; 101: 28252836.
  • 28
    Yazawa S, Madiyalakan R, Izawa H, Asao T, Furukawa K, Matta KL. Cancer-associated elevation of alpha(1[RIGHTWARDS ARROW]3)-L-fucosyltransferase activity in human serum. Cancer 1988; 62: 516520.
  • 29
    Yazawa S, Asao T, Nagamachi Y, Abbas SA, Matta KL. Tumor-related elevation of serum (alpha 1[RIGHTWARDS ARROW]3)-L-fucosyltransferase activity in gastric cancer. J Cancer Res Clin Oncol 1989; 115: 451455.
  • 30
    Chandrasekaran EV, Jain RK, Matta KL. Ovarian cancer alpha 1,3-L-fucosyltransferase. Differentiation of distinct catalytic species with the unique substrate, 3′-sulfo-N-acetyllactosamine in conjunction with other synthetic acceptors. J Biol Chem 1992; 267: 2380623814.
  • 31
    Inaba Y, Ohyama C, Kato T, Satoh M, Saito H, Hagisawa S, et al. Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells. Int J Cancer 2003; 107: 949957.
  • 32
    Weston BW, Hiller KM, Mayben JP, Manousos GA, Bendt KM, Liu R, et al. Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res 1999; 59: 21272135.
  • 33
    Mori S, Aoyagi Y, Yanagi M, Suzuki Y, Asakura H. Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 610619.
  • 34
    Song EY, Kim KS, Kim KA, Kim YD, Kwon DH, Byun SM, et al. Determination of UDP-N-acetylglucosamine: beta-D-mannoside-1,4-N-acetylglucosaminyltransferase-III in patients sera with chronic hepatitis and liver cirrhosis using a monoclonal antibody. Glycoconj J 2002; 19: 415421.
  • 35
    Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, et al. Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998; 124: 2730.
  • 36
    Ito Y, Miyoshi E, Sakon M, Takeda T, Noda K, Tsujimoto M, et al. Elevated expression of UDP-N-acetylglucosamine: alphamannoside beta1,6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer 2001; 91: 631637.
  • 37
    Koenderman AH, Koppen PL, Koeleman CA, van den Eijnden DH. N-acetylglucosaminyltransferase III, IV and V activities in Novikoff ascites tumour cells, mouse lymphoma cells and hen oviduct. Application of a sensitive and specific assay by use of high-performance liquid chromatography. Eur J Biochem 1989; 181: 651655.
  • 38
    Koenderman AH, Wijermans PW, van den Eijnden DH. Changes in the expression of N-acetylglucosaminyltransferase III, IV, V associated with the differentiation of HL-60 cells. FEBS Lett 1987; 222: 4246.
  • 39
    Shim JK, Lee YC, Chung TH, Kim CH. Elevated expression of bisecting N-acetylglucosaminyltransferase-III gene in a human fetal hepatocyte cell line by hepatitis B virus. J Gastroenterol Hepatol 2004; 19: 13741387.